Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Biomaterials. 2018 Oct 20;189:48–59. doi: 10.1016/j.biomaterials.2018.10.022

Figure 5.

Figure 5.

LCP-GMP selectively depleted Tregs without compromising other tumor-infiltrating T cells. B16F10 tumor-bearing mice were given i.v. injections of LCP-GMP, free Gem and control LCP on days 8, 10, 12, 14 post tumor cell inoculation. On day 16, tumors were dissected and processed to single cell suspensions before flow cytometry analysis. The numbers of tumor-infiltrating T cells were normalized to tumor weights. (A) The numbers of tumor-infiltrating CD8+ T cells. *p<0.05, Untreated vs. free Gem; **p<0.01, LCP-GMP vs. free Gem. (B) The numbers of tumor-infiltrating conventional CD4+ Foxp3− T cells (Tconv). *p<0.05, LCP-GMP vs. free Gem; **p<0.005, Untreated vs. free Gem. (C) The numbers of tumor-infiltrating Tregs. *p<0.05, LCP-GMP vs. free Gem; **p<0.01, Untreated vs. LCP-GMP. (D) The ratio of CD8+ T cells to Tregs (CD8/Treg) in tumors. *p<0.05, Untreated vs. LCP-GMP and LCP-GMP vs. free Gem. (E) The ratio of Tconv to Tregs (Tconv/Treg) in tumors. **p<0.005, Untreated vs. LCP-GMP and LCP-GMP vs. free Gem. (n=4 per group).